Drug Trial Radar · NCT06909565
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6,000
Planned (sponsor's estimate)
Start
Jul 23, 2025
Primary completion
Oct 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Duke UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis Pharmaceuticals; Colorado Prevention Center; Mount Sinai Hospital, New York
- First posted
- Apr 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
Conditions
- Percutaneous Coronary Intervention
- Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLDrug
300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter
Normal Saline (Placebo)Drug
Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total number of major adverse cardiovascular events (MACE) after coronary or peripheral endovascular revascularizationTime frame: From randomization to first occurrence of MACE (up to approximately 4 years)
- Total number of major adverse limb events (MALE) after endovascular revascularizationTime frame: From randomization to first occurrence of MALE (up to approximately 4 years)
Locations
153 sites in 1 country. Site status is shown where the registry gives one.
Advanced Cardiovascular LLC
Alexander City, Alabama · Recruiting
Cardiology, PC
Birmingham, Alabama · Recruiting
Heart Center Research, LLC
Huntsville, Alabama · Recruiting
IMS Cardiology
Avondale, Arizona · Recruiting
Cardiology Associates Research Group
Jonesboro, Arkansas · Recruiting
Arkansas Cardiology
Little Rock, Arkansas · Recruiting
Arkansas Heart Hospital
Little Rock, Arkansas · Recruiting
Pacific Oaks Medical Group
Beverly Hills, California · Recruiting
Cardiovascular Institute of San Diego
Chula Vista, California · Recruiting
John Muir Medical Center - Concord Campus
Concord, California · Recruiting
Valley Clinical Trials
Covina, California · Withdrawn
Thrive Clinical Research Group
Glendora, California · Recruiting
Radin Cardiovascular Medical Group, Inc
Newport Beach, California · Recruiting
Amicis Research
Northridge, California · Recruiting
Valley Clinical Trials, LLC - Flourish Research
Northridge, California · Recruiting
Riverside Community Hospital
Riverside, California · Recruiting
Kaiser Permanente - San Diego
San Diego, California · Recruiting
San Diego Cardiac Center
San Diego, California · Recruiting
Sutter Health Heart and Vascular
San Francisco, California · Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California · Recruiting
The Heart Medical Group
Van Nuys, California · Recruiting
FOMAT - West Coast Research Center
Ventura, California · Recruiting
Interventional Cardiology Medical Group
West Hills, California · Recruiting
University of Colorado Anschutz Medical Campus
Aurora, Colorado · Recruiting
Aurora Denver Cardiology Associates - Englewood
Englewood, Colorado · Recruiting
ClinRe 001-001
Thornton, Colorado · Recruiting
Bridgeport Hospital
Bridgeport, Connecticut · Recruiting
Nuvance Health- Danbury Hospital
Danbury, Connecticut · Recruiting
Cardiology Associates of Fairfield County
Stamford, Connecticut · Recruiting
BayCare Medical Group
Clearwater, Florida · Recruiting
Clearwater Cardiovascular Consultants
Clearwater, Florida · Recruiting
Pioneer Clinical Studies
Coral Gables, Florida · Recruiting
Arrow Clinical Trails
Daytona Beach, Florida · Recruiting
Cardiology Research Associates
Daytona Beach, Florida · Recruiting
Vascardio Research
Hialeah, Florida · Recruiting
UF Health Jacksonville
Jacksonville, Florida · Recruiting
East Coast Institute for Research, LLC
Jacksonville, Florida · Recruiting
First Coast Cardiovascular Institute, PA
Jacksonville, Florida · Recruiting
Clearwater Cardiovascular and Interventional Consultants- Bardmoor
Largo, Florida · Recruiting
Inpatient Research Clinic, LLC
Miami Lakes, Florida · Recruiting
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.